Executive summary — what changed and why it matters

Science Corp closed an oversubscribed $230 million Series C on March 5, 2026, bringing total capital raised to roughly $490 million. The financing shifts the company’s posture from lab‑scale research toward clinical expansion and early commercialization for PRIMA, a retinal brain‑computer interface intended to restore central form vision in late‑stage age‑related macular degeneration (AMD).

Thesis: The $230M raise crystallizes a correction: PRIMA is a retinal implant that reframes Science Corp’s trajectory from speculative intracortical BCI research to near‑term ophthalmic commercialization—and that shift will reallocate regulatory scrutiny, surgeon authority, patient expectations, and capital toward established medical‑device pathways.

Key takeaways

• Capital magnitude: The Series C, led by Lightspeed, Khosla, Y Combinator, IQT, and Quiet Capital, provides a large late‑stage capital base to scale clinical programs and early manufacturing.
• Clinical evidence: The lead cohort reported in NEJM (Oct 2025) comprised 19 patients; the study described restoration of functional central vision via a “zoom” feature and documented early post‑operative complications that included elevated intraocular pressure, retinal tears, and bleeding—events reported as largely resolving within two months.
• Regulatory posture: Science Corp has filed a CE‑mark submission for EU commercialization and is prioritizing US FDA interactions; regulatory decisions in the near term are likely inflection points for commercial timelines and market access.
• Strategic distinction: Treating PRIMA as a retinal prosthesis aligns it with ophthalmic surgical workflows, hospital procurement paths, and reimbursement negotiations—different practical realities than intracortical BCI efforts that focus on neurosurgical implantation and long‑term neurophysiological interfaces.
• Human stakes: For patients and clinicians, the pivot emphasizes surgical risk, postoperative vision outcomes, and the social meaning of restored central vision; for communities and regulators, it reframes questions of device classification, follow‑up burden, and consent around ocular rather than intracranial risk.

Breaking down the announcement — what the funding enables and reorders

The $230M Series C is explicitly described as financing three tracks: EU commercial launch activity contingent on a CE mark, expanded US clinical programs and regulatory engagement, and continued R&D on adjacent platform technologies. The size and timing of the round change the company’s available strategic options. Large late‑stage financing makes earlier choices—market positioning as an ophthalmic device, surgical adoption strategies, and near‑term revenue orientation—more likely to be binding rather than exploratory.

That binding effect matters because it reallocates internal priorities and external expectations. Investors and executives typically shorten timelines when large capital commitments demand returns; clinicians and regulators then encounter an acceleration in real‑world use that tests trial assumptions. Recasting PRIMA as a retinal implant means the company will operate in an ecosystem where ophthalmologists, hospital device committees, and payers exercise decision authority rather than the research networks that typically shepherd intracortical BCI prototypes.

Clinical results and risks — anchoring the evidence

The principal peer‑reviewed evidence to date is the NEJM publication (Oct 2025) reporting outcomes from a 19‑patient cohort. That study described restored functional central vision enabled by an implanted retinal device with a “zoom” capability. The same cohort produced early surgical complications: elevated intraocular pressure, retinal tears, and bleeding. The NEJM report indicated these complications were largely resolved within approximately two months for the cohort described.

Interpreting a 19‑patient cohort requires discipline: the results are suggestive of meaningful function restoration for some patients, but they are small by clinical‑development standards and limited in duration. Practically, the NEJM cohort can demonstrate proof of concept and establish an early safety profile, but it does not define long‑term durability, population‑level adverse‑event rates, or the heterogeneity of outcomes across surgical centers and patient subgroups. Each of those unknowns carries weight for patient consent, surgeon training, and payer assessments.

Why the retinal correction matters for regulation and care pathways

Labeling PRIMA as a retinal implant—rather than an intracortical brain implant—is not a semantic quibble. It changes the dominant regulatory analogies, the likely surgical pathway, and the institutions that will adjudicate access. Retinal devices are commonly reviewed through ophthalmic device frameworks and adopted through ophthalmology operating theaters, which implies different expectations around perioperative care, device sterility, and postoperative monitoring than intracortical systems that sit squarely in neurosurgery and neurotechnology oversight.

The regulatory consequence is twofold. First, device reviewers will look to retinal prostheses and intraocular device precedents when assessing risk‑benefit, labeling, and contraindications. Second, regulators and payers will likely request follow‑up evidence tailored to ocular outcomes and complications—extended IO pressure monitoring, retinal integrity assessments, and rates of vitrectomy or reoperations—rather than the neurophysiological measures that dominate intracortical filings. That focus will shape trial design, post‑market surveillance, and what counts as acceptable evidence for coverage decisions.

Competitive and market context

Science Corp’s strategic posture contrasts with intracortical BCI companies pursuing generalized brain interfaces and automated volumetric production. The retinal route narrows the initial patient population to late‑stage AMD and related retinal degenerations, which concentrates clinical efficacy questions but offers a clearer path to existing care pathways and reimbursement codes. Narrower indications reduce the breadth of potential benefit but increase the relevance of ophthalmic clinical networks and health system purchasing decisions.

For patients, the tradeoff is between a focused, near‑term therapeutic possibility and the unknowns of surgical complications and functional durability. For clinicians and health systems, the tradeoff is between a device that fits into existing ophthalmology practice and the resource demands of postoperative monitoring and potential reoperations. For regulators and payers, the tradeoff is between precedent‑based evaluation and the novel aspects of a visual‑restoration implant that interfaces with the brain’s visual pathway.

What to watch next

• CE‑mark decision and timing of first EU implants—these will be the clearest signals of whether regulators and clinical centers accept the device as an ophthalmic technology in practice.
• FDA interactions—submissions, questions, and whether any expedited pathways are pursued or granted will indicate the US regulatory appetite for retinal BCI commercialization.
• Post‑market safety reports and real‑world complication rates beyond the 19‑patient NEJM cohort, including longer‑term IO pressure trends, retinal stability, and rates of reoperation.
• Evidence of manufacturing scale: device yields, supply‑chain readiness, and the logistics of surgical kit distribution that determine whether implants can move from single‑center feasibility to multi‑site deployment.
• Early payer signals on reimbursement, coding, and eligibility criteria that will shape patient access and clinical adoption rates.

Implications for stakeholders (diagnostic, not prescriptive)

• Implication for patients and patient advocates: Framing PRIMA as an ophthalmic device will likely foreground surgical risk profiles, postoperative vision metrics, and consent discussions focused on ocular complications and functional expectations—raising questions about how restored central vision will affect patients’ independence, identity, and quality of life.
• Implication for ophthalmologists and surgical teams: A move toward CE‑mark commercialization implies increased demand for surgical training, credentialing, and shared decision frameworks; surgical authority and local hospital policies will shape who receives early implants and under what safeguards.
• Implication for regulators: The retinal classification raises the likelihood that authorities will request ocular‑specific follow‑up datasets and longer safety windows, pressing regulators to reconcile device precedent with novel neural‑interface claims.
• Implication for payers and health systems: Early commercialization pressures could prompt payers to demand real‑world evidence and narrowly defined eligibility criteria; health systems will face decisions about resource allocation for postoperative monitoring and the ethics of offering experimental restorative vision services.
• Implication for investors and corporate strategy: Large late‑stage capital will likely compress timelines toward revenue generation, increasing scrutiny on manufacturing readiness and clinical program scaling; investors will be watching regulatory milestones as valuation hinge points rather than pure R&D milestones.

Bottom line

The $230M Series C materially changes the vector of Science Corp’s project. Treating PRIMA as a retinal implant reframes the company’s relationship to regulators, clinicians, patients, and payers: it moves the work from exploratory neuroscience into the apparatus of medical‑device commercialization. That shift does not resolve clinical unknowns—the NEJM (Oct 2025) 19‑patient cohort is suggestive but small, and it included early complications that were reported to resolve within two months—but it does accelerate the social and institutional questions that determine whether restored central vision becomes an available, scalable therapy or an expensive, contested niche.

In short, the financing is both a vote of confidence and a structural forcing mechanism: it makes ophthalmic pathways, surgical authority, and regulatory scrutiny the central axes around which PRIMA’s future will be decided, with high stakes for patient autonomy, clinician responsibility, and who holds decision‑making power over access to a new form of restored vision.